Since its incorporation, the NeuroPsyAI team, has worked towards creating a stand-alone software device that performs automated labeling, visualization and quantification of structural features (such as, but not limited to, volumetric and diffusion data) in segmental brain magnetic resonance (“MR”) images (up to 3T, inclusive). Like its competitors, it also compares the result of a specific measurement of brain tissue and structures to a normative patient brain MR data sets and can display them in a comprehensive report. Contrary to the competitor software, the NeuroPsyCAD device runs proprietary algorithms and it outputs, to the user, the inferred probability score of the association with a specific neurological disease and will be intended to aid the diagnosis of a specific neurological condition. This is a novel intended for use that brings forward the technological capability that set it apart from other commercially available brain tissue and structures measurement tools. It will be labeled as a CDSS: Clinical Decision Support System as it is intended to inform the user about the probability of the patient suffering from a specific neurological condition. It will provide additional diagnostic insights on top of the standard of care decision making work flow. In addition to the diagnostic claim, the device will also be intended in a manner that is like its competitors to the end that it also intended for automatic labelling, visualization and volumetric quantification of segmental brain structures from a set of MR images.
At present time, the company is perfecting its algorithms for Alzheimer’s (including discerning mild cognitive impairment), Fronto Temporal Dementia (“FTD”), Parkinson’s and Parkinsonian syndromes. The company is also expanding its collaborations and partnerships with renowned clinicians and hospitals to advance our work and preparing a commercialization strategy.
NeuroPsyCAD’s software could create a much higher demand for MRI, which will commercially benefit MRI manufacturers and generate savings to the healthcare system as a result of streamlining diagnosis. In the case of FTD (front temporal dementia) the clinical need is stronger as the disease if very challenging to diagnose currently and more expensive modalities are utilized to aid its detection (Functional MRI). The role of MRI imaging in Parkinson disease is so far very limited and transitioning from expensive PET scanner to MRI could result in significant cost savings.
